Top-News

Novelion Therapeutics News

Keine aktuellen Kursdaten verfügbar
WKN: A2DJKD
ISIN: CA67001K2020
US-Symbol: NVLN
Typ: Aktie

Novelion Therapeutics News

12.11.18 - PR Newswire
Is it time to buy stock in Aurora Cannabis Inc, Advanced Micro Devices, General Electric, Novelion Therapeutics or Tesla Inc.?
Is it time to buy stock in Aurora Cannabis Inc, Advanced Micro Devices, General Electric, Novelion Therapeutics or Tesla Inc.? PR Newswire
09.11.18 - PR Newswire
Thinking about buying stock in Advanced Micro Devices, ARRIS Group Inc., General Electric, Novelion Therapeutics or Square Inc.?
Thinking about buying stock in Advanced Micro Devices, ARRIS Group Inc., General Electric, Novelion Therapeutics or Square Inc.? PR Newswire
25.06.18 - GlobeNewswire
Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions Data Show Leptin Replacement Therapy ...
01.06.18 - GlobeNewswire
MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy Europe represents potentially the largest market for metreleptin ...
31.03.18 - GlobeNewswire
Novelion Therapeutics Supports World Lipodystrophy Day
Novelion Therapeutics Supports World Lipodystrophy Day VANCOUVER, British Columbia, March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a ...
28.02.18 - GlobeNewswire
Novelion Therapeutics Observes Rare Disease Day
Novelion Therapeutics Observes Rare Disease Day Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare ...
22.12.16 - GlobeNewswire
Novelion Therapeutics' Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy
Novelion Therapeutics' Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy - If ...
30.06.14 - PR Newswire
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Auxilium Pharmaceuticals Inc. and Its Board of Directors In Connection With the Sale of the Company to QLT Inc. -- AUXL
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Auxilium Pharmaceuticals Inc. and Its Board of Directors In Connection With the Sale of the Company to QLT ...
26.06.14 - PR Newswire
Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT
Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty ...
24.09.12 - PR Newswire
Valeant Pharmaceuticals Acquires Visudyne® From QLT
Valeant Pharmaceuticals Acquires Visudyne® From QLT PR Newswire
02.09.10 - Aktiencheck
QLT "buy" - C.K. Cooper & Company
Rating-​Update: Irvine (aktiencheck.de AG) - Die Analysten von C.K. Cooper & Company stufen die Aktie von QLT in einer Ersteinschätzung mit "buy" ein. Das Kursziel werde bei 12 ...
22.04.10 - Aktiencheck
QLT "buy" - Roth Capital
Rating-​Update: Newport Beach (aktiencheck.de AG) - Die Analysten von Roth Capital stufen die Aktie von QLT in einer Ersteinschätzung mit "buy" ein. Das Kursziel werde bei 14 USD ...
27.11.09 - Aktiencheck
QLT Upgrade - RBC Capital Markets
Rating-​Update: Toronto (aktiencheck.de AG) - Douglas Miehm, Analyst von RBC Capital Markets, stuft die Aktie von QLT von "sector perform" auf "outperform" hoch. Das Kursziel ...
02.02.09 - Aktiencheck
QLT "sector perform" - RBC Capital Markets
Rating-​Update: Toronto (aktiencheck.de AG) - Die Analysten von RBC Capital Markets stufen die Aktie von QLT unverändert mit "sector perform" ein. Das Kursziel werde von 3 auf ...
22.01.08 - Aktiencheck
QLT "outperform" - BMO Capital Markets
Rating-​Update: Toronto (aktiencheck.de AG) - Die Analysten von BMO Capital Markets stufen die Aktie von QLT von "market perform" auf "outperform" hoch. (22.01.2008/ac/a/u)
18.01.08 - aktiencheck
QLT entlässt 45 Prozent seiner Mitarbeiter
30.10.07 - Aktiencheck
QLT neues Kursziel - BMO Capital Markets
Rating-​Update: Toronto (aktiencheck.de AG) - Die Analysten von BMO Capital Markets stufen die Aktie von QLT Inc. unverändert mit "market perform" ein. Das Kursziel werde von 6,80 ...
20.04.07 - Aktiencheck
QLT Inc. neutral - UBS
Rating-​Update: Zürich (aktiencheck.de AG) - Die Analysten der UBS stufen die Aktie von QLT Inc. von "reduce" auf "neutral" hoch. (20.04.2007/ac/a/u)
26.02.07 - Aktiencheck
QLT neues Kursziel - BMO Capital Markets
Rating-​Update: Toronto (aktiencheck.de AG) - Die Analysten von BMO Capital Markets stufen die Aktie von QLT unverändert mit "market perform" ein. Das Kursziel werde von 9,29 auf ...
31.10.06 - Aktiencheck
QLT "outperform" - BMO Capital Markets
Rating-​Update: Toronto (aktiencheck.de AG) - Die Analysten von BMO Capital Markets stufen die Aktie von QLT (ISIN CA7469271026/ 877927) von "market perform" auf "outperform" ...

Newssuche

Videos

newspaper
25.04.24 +21,95%
Technical Trading: S&P 500 Short Chance
S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »